ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor

Han, Rui*; Yang, Hongxing; Ling, Changquan; Lu, Lingeng*广州中医药大学; 1
Cancer Cell International2022-11-24DOI: 10.1186/s12935-022-02786-6
6被引5阅读
引用收藏
分享

摘要

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by poor prognosis, early recurrence, and the lack of durable chemotherapy responses and specific targeted treatments. In this preclinical study, we examines Tiliroside (TS, C30H26O13), as one of the major compounds of Tribulus terrestris L. which has been used as an alternative therapy in clinic practice of breast cancer treatment, for its therapeutic use in TNBC. The association between CAXII expression level and survival probability of TNBC patients, and the difference of CAXII expression level between TNBC and normal samples were evaluated by using publicly accessible databases. To determine the anticancer efficacy of TS on TNBC cells, cell proliferation, wound healing, cell invasion, and 3D spheroid formation assays were performed and excellent anticancer activities of TS were displayed. Mouse models further demonstrated that TS significantly reduced the tumor burden and improved survival rate. The properties of TS as a novel CAXII inhibitor have also been evaluated by CAXII activity assay, pHi, pHe and lactate level assay. Further RT-PCR and Caspase-3 activity analyses also revealed the positive regulating effects of TS on E2F1,3/Caspase-3 axis in TNBC cells cultured in 2D or 3D systems. The findings indicate that TS suppresses TNBC progression as a potential novel CAXII inhibitor in preclinical experiments, which warrants further investigation on its therapeutic implications.

学科与关键词

关键词
TNBCCAXII inhibitorTilirosideCancer stemnessApoptosis
相关
加载中…
  • Inhibition of growth and metastasis of triple-negative breast cancer targeted by Traditional Chinese Medicine Tubeimu in orthotopic mice models.
    Wang, Jingxiao; Yang, Xinjie; Han, Haibo; Wang, Limin; Bao, Weiqian; Wang, Shanshan; Hoffman, Robert M; Yang, Meng; Qi, Hui; An, Chao; Hu, KaiwenChin J Cancer Res, 2018, 30(1): 112-121.
  • In Vitro and In Vivo Anti-Cancer Activity of Lasiokaurin in a Triple-Negative Breast Cancer Model
    Lin, Jinrong; Qu, Zhao*; Pu, Huanhuan; Shen, Li-Sha; Yi, Xianguo; Lin, Yu-Shan; Gong, Rui-Hong; Chen, Guo-Qing*; Chen, Sibao*MOLECULES, 2023, 28(23): 7701.
  • Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF? signaling pathway
    Zhang, Yuzhu; Chen, Jing; Mi, Dazhao; Ling, Jun; Li, Huachao; He, Peng; Liu, Ning; Chen, Qianjun*; Chen, Yihua*; Huang, Luqi*Cancer Letters, 2023, 560: 216142.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Cell International
发表日期
2022-11-24
卷期
第 22 卷, 第 1 期
页码
368
DOI
10.1186/s12935-022-02786-6
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China Youth Fund [82204864]

作者

  • H

    Han, Rui (通讯) (第一作者)

    1 · new

  • Y

    Yang, Hongxing

    1 · guangzhou univ chinese med

查看全部 4 位作者收起作者
  • L

    Ling, Changquan

    1

  • L

    Lu, Lingeng (通讯)

    new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417